Fundraising Fox
Veradermics
NYSE: MANEWest Hartford, US · Founded 2021 · Delaware corporation · 7 known investors
Find your way into Veradermics
Sign up to see every warm intro you have to Veradermics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Veradermics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men. The therapy is being evaluated in Phase 2 and Phase 3 clinical trials.
Founders & leadership
Veradermics was founded in 2021 by Reid Waldman.
RW
Reid WaldmanFounderReid Waldman is a board-certified dermatologist who founded Veradermics to develop improved treatments for pattern hair loss. He completed a BA/MD through the University of Missouri–Kansas City and a dermatology residency at the University of Connecticut, and has authored over 100 peer-reviewed publications in dermatology.30 Under 30 2024
TD
Tim DursoChief Technical OfficerTim Durso is a board-certified dermatologist with over 10 years of clinical experience who co-founded Veradermics with Reid Waldman. As Chief Technical Officer, he leads research and development for the company's pipeline including VDPHL01, an oral minoxidil therapeutic in Phase 3 clinical trials for pattern hair loss.
MN
Mark NeumannChief Commercial and Strategy Officer
JW
John W. ChildsNamed on SEC filing
JG
Jane Grant-KelsNamed on SEC filing
VC
Vladimir CoricNamed on SEC filing
Investors · 7
Longitude Capital✓ confirmed by VeradermicsMenlo Park · $10M – $30M
How we know: the company's own site · Longitude Capital's portfolio page · the S-1 prospectus · funding news · the VCSheet dataset · Not right? Tell us
Connecticut Innovationslisted by Connecticut InnovationsNew Haven · $500K – $2M
How we know: Connecticut Innovations's portfolio page · Not right? Tell us
LifeSci Venture Partnerslisted by LifeSci Venture PartnersNew York
How we know: LifeSci Venture Partners's portfolio page · funding news · Not right? Tell us
OUP (Osage University Partners)listed by OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us
SR One Capital Managementlisted by SR One Capital ManagementRedwood City
How we know: SR One Capital Management's portfolio page · Not right? Tell us
abrdn plcreportedEdinburgh
How we know: funding news · Not right? Tell us
InvusreportedNew York
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$269.3M disclosed across 6 rounds · 2020–2026
▶$30MraisedMay 2026 · 2 investors · Other Health CareRule 506(b)
▶$30MraisedMay 2026 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- PATRICK ENRIGHTDirector
- DAVID FRIEDMANDirector
- JOHN CHILDSDirector
- JANE GRANT-KELSDirector
- VLADIMIR CORICDirector
- MICHAEL GRECOExecutive Officer
- REID WALDMANExecutive Officer, Director
- KATARINA PANCEDirector
- MARK NEUMANNExecutive Officer
- DOMINIC CARRANOExecutive Officer
- TIM DURSOExecutive Officer
- Offering amount
- $30M
- Amount sold
- $30M
- Sales commissions
- $1.8M
- Placement agents
- JEFFERIES LLC, LEERINK PARTNERS LLC, CITIGROUP GLOBAL MARKETS INC., CANTOR FITZGERALD & CO., LIFESCI CAPITAL, NEEDHAM & COMPANY, LLC
- First sale
- May 2026
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$135MraisedOct 2025 · 40 investors · Other Health CareRule 506(b)
▶$135MraisedOct 2025 · 40 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Patrick EnrightDirector
- Katarina PanceDirector
- Amanda Birdsey-BensonDirector
- John ChildsDirector
- Vladimir CoricDirector
- Jane Grant-KelsDirector
- Reid WaldmanExecutive Officer, Director
- Offering amount
- $150M
- Amount sold
- $135M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$66.6MraisedDec 2024 · 40 investors · Other Health CareRule 506(b)
▶$66.6MraisedDec 2024 · 40 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jane Grant-KelsDirector
- Reid WaldmanExecutive Officer, Director
- Amanda Birdsey-BensonDirector
- Christopher EklundDirector
- Vladimir CoricDirector
- Patrick EnrightDirector
- John W. ChildsDirector
- Offering amount
- $75M
- Amount sold
- $66.6M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$15MraisedMay 2023 · 16 investors · Other Health CareRule 506(b)
▶$15MraisedMay 2023 · 16 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John W. ChildsDirector
- Reid WaldmanExecutive Officer, Director
- Jane Grant-KelsDirector
- Vladimir CoricDirector
- Timothy DursoExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$22.2MraisedOct 2021 · 41 investors · Other Health CareRule 506(b)
▶$22.2MraisedOct 2021 · 41 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Vladimir CoricDirector
- Reid WaldmanExecutive Officer, Director
- Jane Grant-KelsDirector
- John W. ChildsDirector
- Timothy DursoExecutive Officer, Director
- Offering amount
- $22.2M
- Amount sold
- $22.2M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$476.1KraisedOct 2020 · 1 investors · Other Health CareRule 506(b)
▶$476.1KraisedOct 2020 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Timothy DursoExecutive Officer, Director
- Reid WaldmanExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $476.1K
- First sale
- Sep 2020
- Incorporated
- Corporation, Texas, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Veradermics went on to found or lead other companies.
Related companies · 3
AllureAllure is a beauty journalism publication that provides product reviews, trend reporting, and expert guidance on makeup, hair, skincare, and wellness. The publication serves beauty consumers and industry professionals through its website, social channels, and subscription service.
Hims & HersUS direct-to-consumer telehealth company selling prescription and OTC treatments online by subscription; NYSE-listed as HIMS.
RoRo is an online healthcare platform that connects patients with licensed providers and delivers prescription treatments, including GLP-1 medications for weight loss, ED treatments, and other health goals. The direct-to-consumer telehealth service is fully online and serves individual patients in the United States.
Companies working in the same space as Veradermics.
In the news
Frequently asked questions
- What does Veradermics do?
- Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men. The therapy is being evaluated in Phase 2 and Phase 3 clinical trials.
- Who founded Veradermics?
- Veradermics was founded by Reid Waldman in 2021.
- Who are Veradermics's investors?
- Veradermics's investors include Longitude Capital, Connecticut Innovations, LifeSci Venture Partners, OUP (Osage University Partners), SR One Capital Management, abrdn plc, Invus.
- How much funding has Veradermics raised?
- Veradermics has disclosed $269.3M raised across 6 rounds.
- Where is Veradermics headquartered?
- Veradermics is headquartered in West Hartford, US.